CCL acquisition
Since the beginning of this year, Icon and Nuffield Health have been working closely to build on existing services and enhance patient care at CCL. This acquisition is a natural next step in the collaboration and reflects both organisations’ commitment to improving cancer care in the UK.
Icon Group CEO, Mark Middleton OAM said the acquisition reflects a confidence in the partnership.
“This acquisition is a direct result of Icon’s proven ability to partner and enhance cancer care services alongside local insights and experienced clinical teams,” said Mark.
“Combining Nuffield Health’s deep healthcare experience and pathways with Icon’s specialist capability in cancer treatment, increases patient access to world-class care at a critical time in the UK.”
Nuffield Health CEO, Alex Perry is looking forward to welcoming CCL’s next chapter.
Alex said: “As cancer diagnoses continue to rise across the country, we are collaborating with Icon to create sector-leading cancer care pathways, ensuring the delivery of integrated cancer care alongside our existing oncology services. The Icon team has already done amazing work at CCL to deliver cutting-edge cancer treatment and an enhanced patient experience. This fantastic facility, team, and patients will be in the very best hands.”
“We’re also excited that our Nuffield Health Parkside hospital and CCL will continue to work in partnership to offer comprehensive cancer care – from surgery at Parkside through to treatment and ongoing wellbeing support at CCL next door. With cancer diagnoses rising across the country, we will also continue to work with Icon to further our partnership and develop sector leading opportunities and care pathways to tackle these challenges head on.”
